Boston Scientific Corporation (BSX): one to watch?

Watch, don't buy yet — repeated guidance cuts show real growth deceleration, and it's unclear if the bleeding has stopped.

👀 WATCH Fundamentals70/100

Down 52% from its all-time high of $107.22 — now $51.83

Why BSX dropped

Shares are down over 50% from their September 2025 peak after management cut full-year revenue guidance three times in a row (most recently to just 5.5%-6.5% growth from an original 10.5%-11.5%), driven by slowing Watchman heart-implant device sales and competitive pressure in its electrophysiology (heart rhythm) business, plus several product recalls raising quality-control concerns.

Fwd P/E 15.1Op margin 22.9%Rev growth 7.5%Debt/equity 50.2%Analyst upside 21.0%

How this scored 70/100

✅ Passes all 4 hard checks — profitable, cash-generative, and financially survivable.

✅ Makes money Net profit margin 17.5%

✅ Generates cash Free cash flow $2.5B

✅ Not drowning in debt Debt/equity 50.2% (limit 200%)

✅ Can pay its bills Current ratio 1.2 (needs 1+)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 19/25

Operating margin 22.9% 8/9

Net profit margin 17.5% 7/8

Return on equity 15.3% 4/8

Growth Is it getting bigger, or dying? 17/25

Revenue growth 7.5% 4/9

Earnings growth 15.1% 5/8

Expected profit change 39.2% 8/8

Value Is it cheap right now? 17/25

Forward P/E 15.1 8/10

PEG ratio 0.7 7/8

Analyst target upside 21.0% 2/7

Balance sheet Will it survive? 17/25

Debt / equity 50.2% 8/10

Current ratio 1.2 1/8

Free cash flow $2.5B 7/7

🔒 Read the full AI analysis

Create a free account to unlock the bull case and the risks for BSX — plus today's other picks.

Analysis generated by SmartStonks's AI from public fundamentals and news, first flagged 2026-08-17. Research only — not financial advice.